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Abstract
Background: Neonates have dampened expression of pro-inflammatory cytokines and difficulty clearing
pathogens. This makes them uniquely susceptible to infections, but the factors regulating neonatal-specific immune
responses are poorly understood. Epigenetics, including histone modifications, can activate or silence gene
transcription by modulating chromatin structure and stability without affecting the DNA sequence itself and are
potentially modifiable. Histone modifications are known to regulate immune cell differentiation and function in
adults but have not been well studied in neonates.
Results: To elucidate the role of histone modifications in neonatal immune function, we performed chromatin
immunoprecipitation on mononuclear cells from 45 healthy neonates (gestational ages 23–40 weeks). As gestation
approached term, there was increased activating H3K4me3 on the pro-inflammatory IL1B, IL6, IL12B, and TNF
cytokine promoters (p < 0.01) with no change in repressive H3K27me3, suggesting that these promoters in preterm
neonates are less open and accessible to transcription factors than in term neonates. Chromatin
immunoprecipitation with massively parallel DNA sequencing (ChIP-seq) was then performed to establish the
H3K4me3, H3K9me3, H3K27me3, H3K4me1, H3K27ac, and H3K36me3 landscapes in neonatal and adult CD14+
monocytes. As development progressed from neonate to adult, monocytes lost the poised enhancer mark
H3K4me1 and gained the activating mark H3K4me3, without a change in additional histone modifications. This
decreased H3K4me3 abundance at immunologically important neonatal monocyte gene promoters, including CCR2,
CD300C, ILF2, IL1B, and TNF was associated with reduced gene expression.
Conclusions: These results provide evidence that neonatal immune cells exist in an epigenetic state that is
distinctly different from adults and that this state contributes to neonatal-specific immune responses that leaves
them particularly vulnerable to infections.
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Background
Neonates are uniquely susceptible to infections, with
preterm infants (born before 37 weeks of gestation) being
the most vulnerable [1]. Up to 25 % of extremely preterm
infants develop a culture-positive bacterial infection during
their initial hospitalization, which increases their risk of
death and long-term neurodevelopmental impairment [2].
Neonatal susceptibility to infection is thought to be due to
the need for invasive but life-saving medical interventions,
immaturity of the immune system, and disordered regula-
tion of inflammation [3, 4].
Protection against infection occurs through the
combined efforts of the innate and adaptive immune
systems. Monocytes, which mature into macrophages in
the tissues, are part of the innate immune system and
act as the first line of defense, sensing pathogens and
presenting them to cells of the adaptive immune system.
Type 1 macrophages express pro-inflammatory cyto-
kines, exhibit strong phagocytic activity, and contribute
to the acute inflammatory response, resulting in clear-
ance of pathogens. In contrast, type 2 macrophages
express anti-inflammatory cytokines, contribute more to
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the maintenance of chronic inflammation and tissue
fibrosis, and are less efficient at clearing pathogens [5].
There is a predominance of type 2 cytokine expression
during most normal pregnancies, thought to suppress
cellular immunity and protect the fetus from abortive
responses [6]. This type 2 cytokine predominance
continues in the newborn for several weeks after delivery
and in the preterm infant may be prolonged [7]. In
neonates, this type 2 skew results in dampened produc-
tion of the pro-inflammatory cytokines IL-1β, IL-6,
IL-12, and TNF-α, impacting their ability to fight infec-
tions and clear pathogens [8–12]. Mechanisms control-
ling developmentally related innate immune system
phenotype differences are poorly understood.
Epigenetics studies how genetic and environmental fac-
tors interact to alter DNA structure without affecting the
underlying genetic code. Epigenetic modifications include
DNA methylation, histone modifications, and microRNA
expression. These modifications collectively activate or
silence gene transcription by influencing chromatin struc-
ture and stability or by altering how DNA interacts with
transcription factors. The amino acid that is most often
modified in histones is lysine, and its position in the
histone tail can determine if the added modification allows
an open or closed configuration of the gene. The addition
of three methyl groups on lysine (K) 4 of histone (H) 3
(i.e., H3K4me3) leads to activation of gene transcription.
H3K9me3 and H3K27me3 are both associated with gene
silencing as they promote chromatin compaction and
make gene promoters inaccessible to transcription factors
[13, 14]. H3K4me1 indicates poised enhancers while
acetylation of H3K27 (i.e., H3K27ac) marks active
enhancers, both of which serve as distal regulators of gene
expression [15, 16]. H3K36me3 is associated with either
activation or inhibition of gene transcription based on
surrounding marks [17].
Histone modifications have been found to underlie
normal developmental changes in the immune system,
contributing to cell lineage decisions and influencing
how cells respond to external stimuli [15, 18]. There has
been increasing interest in developmental-specific epi-
genetic events that may underlie the unique responses of
the neonatal immune system, and some work has
evaluated how DNA methylation and microRNA expres-
sion impact these responses in term neonates [19, 20].
Our work is the first to investigate the role of histone
modifications in the development and maturation of the
neonatal immune system. We demonstrate that in
monocytes, a decrease in the poised enhancer mark
H3K4me1 parallels an increase in the active promoter
mark H3K4me3 as development progresses from
neonate to adult. We also show that a lack of H3K4me3
in neonatal monocytes is associated with a reduction in
gene expression in vital immunologic pathways. These
findings suggest that the unique histone modification
landscape in neonatal monocytes may be contributing to
the heightened infection risk present in the neonatal
period.
Results
H3K4me3 increases at mononuclear cell cytokine
promoters as development progresses
To determine if histone modifications contribute to the
attenuated pro-inflammatory responses observed in pre-
term neonates, we performed a chromatin immunopre-
cipitation assay (ChIP) using anti-H3K4me3 and anti-
H3K27me3 antibodies to evaluate the promoter regions
of the pro-inflammatory cytokine genes IL1B (Fig. 1a),
IL6 (Fig. 1b), IL12B (Fig. 1c), and TNF (Fig. 1d). The
activating histone modification H3K4me3 was signifi-
cantly increased on the promoters of all four cytokines
in term infants, compared to extremely preterm infants
(Fig. 1). There was no change in the repressive histone
modification H3K27me3 over development on any of
the promoters analyzed (Fig. 1). These findings suggest
that the IL1B, IL6, IL12B, and TNF promoters of the
preterm innate immune system are less accessible to
transcription factors than in term neonates, which may
contribute to the attenuated pro-inflammatory responses
exhibited by preterm infants.
The abundance and location of monocyte H3K4me3
changes throughout development
To determine the overall profile of H3K4me3 in innate
immune cells throughout development, we performed
chromatin immunoprecipitation with massively parallel
DNA sequencing (ChIP-seq), allowing us to identify all
H3K4me3 sites in the monocyte genome. We evaluated
the global distribution of H3K4me3 in CD14+ mono-
cytes from four experimental groups: under 30-week
preterm infants (U30), over 30-week preterm infants
(O30), term infants (Term), and healthy adults (Adult).
Figure 2 summarizes the differences in H3K4me3
deposition in monocytes among different developmental
stages. A principle component analysis of the H3K4me3
monocyte peak locations and affinity for these locations
shows that the preterm monocytes cluster together, the
term monocytes cluster together, and the adult mono-
cytes cluster together, but these three groups are distinct
from each other both in location and abundance of
H3K4me3 (Fig. 2a). A closer look at the total amount of
H3K4me3 in the monocyte genome shows that there is
an increase in total number of H3K4me3 peaks as
development progresses toward term, although the term
neonates still have significantly less H3K4me3 than the
adults (Fig. 2b). To obtain a broad view of H3K4me3
distribution, we divided the human genome into four
distinct categories according to the UCSC Genome
Bermick et al. Clinical Epigenetics  (2016) 8:99 Page 2 of 15
Browser known genes: promoters (1 kb upstream or
downstream from transcriptional start sites (TSSs)),
exons, introns, and intergenic regions [21, 22]. The
majority of H3K4me3 peaks in the preterm monocytes
were located in introns and intergenic regions, with less
than 5 % of the peaks associated with promoters and
exons. There were slightly more H3K4me3 peaks
associated with promoter and exon sites in the term
monocytes, ~15 %, although the majority were still
located in noncoding regions of the genome. In contrast,
the adult monocytes had the majority of their H3K4me3
peaks located at promoters and exons (70 %), with only
a minority in other regions of the genome (Fig. 2c). Over
75 % of the intergenic H3K4me3 peaks present in the
neonatal monocytes were also present in the adult
monocytes, suggesting that the intergenic neonatal peaks
remained stable as development progressed and that the
majority of new H3K4me3 peaks acquired were in
promoter and exon locations. The total number of peaks
in each location is detailed in Additional file 1: Table S1.
H3K4me3 is associated with distinctly different gene
ontology pathways in neonatal and adult monocytes
A large proportion of H3K4me3 peaks in the monocytes
of all age groups were associated with gene pathways
required for cell survival and basic function including
metabolism, cell structure, cell signaling, and intra-
cellular transport (Fig. 3a). The major gene ontology
pathways that changed over the course of maturation in-
cluded developmentally related pathways and immuno-
logically important pathways (Fig. 3a). The preterm
monocytes had 30–35 % of their H3K4me3 peaks associ-
ated with developmentally important pathways, includ-
ing pathways involved in spinal cord, heart, and renal
development. The term monocytes had approximately
10 % of their H3K4me3 peaks associated with develop-
mentally important pathways, while the adult monocytes
had no peaks associated with these pathways. Con-
versely, the U30 monocytes had no H3K4me3 peaks as-
sociated with immunologically important pathways,
including responses to pathogens, cytokine and chemo-
kine production, and antigen presentation. The O30
monocytes had less than 1 % (4 total) of H3K4me3 peaks
associated with immunologically important pathways,
while the term monocytes had approximately 6 % (30
total) and the adult monocytes had around 8 % (57
total). The immunologically important pathways
enriched for H3K4me3 are detailed in Additional file 1:
Table S2, and the top ranking gene ontology biological
pathways enriched for H3K4me3 by age group are
shown in Fig. 3b–e. Of note, interferon responsive genes,
including IFNB1, CXCL10, and ISG15, did not have
differentially bound H3K4me3 between neonatal and
adult monocytes.
There were numerous microRNA (miR) promoters
with increased H3K4me3 peaks in the adult monocytes.










































































Fig. 1 The activating histone modification H3K4me3 increases on pro-inflammatory cytokine promoters as development progresses over the third
trimester. ChIP assays were performed to determine the H3K4me3 and H3K27me3 profiles throughout fetal development of the a IL1B promoter,
b IL6 promoter, c IL12B promoter, and d TNF promoter. <30 n = 25, 30–36 n = 10, 37+ n = 10. *p < 0.05, **p < 0.01. Box represents 25th–75th percentile
range, and whiskers represent minimum to maximum values
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miR-21 is the lone miR identified with known immune
function and is involved in the negative regulation of
TLR4 signaling [23]. All miRs with differential binding
between adult and neonatal monocytes are listed in
Additional file 1: Table S3. Immune cell activation re-
quires a metabolic shift from oxidative phosphorylation to
glycolysis or lipid metabolism to account for the up-
regulation of a large number of inflammatory genes, and
neonatal immune cells have difficulty undergoing this
metabolic shift effectively [24–26]. As a large proportion
of H3K4me3 peaks gained over the course of development
are in metabolic pathways, we evaluated if differentially
bound H3K4me3 peaks between term neonatal and adult
monocytes could account for the differences in their
ability to undergo this critical metabolic shift. We found
multiple genes crucial to glycolysis and lipid metabolism
with increased H3K4me3 binding in adult monocytes
(Additional file 1: Table S4). The gene ontology pathways
associated with H3K4me3 peaks present only in the adult
monocytes are outlined in Additional file 2: Figure S1.
A decline in monocyte H3K4me1 parallels an increase in
H3K4me3 during development
To evaluate if histone modifications other than H3K4me3
change significantly over the course of development, we
took advantage of ChIP-seq datasets from the Blueprint
project (large scale research project generating reference
epigenomes for mechanistic studies of health and disease).
The Blueprint project has performed ChIP-seq experi-
ments targeting common histone modifications in both
adult monocytes and monocytes from term neonatal
umbilical cord blood. These experiments include immu-
noprecipitation of the suppressive marks H3K9me3 and
H3K27me3, the enhancer marks H3K4me1 and H3K27ac,
and the more versatile mark H3K36me3, which can serve
as both an activating and repressive mark. Each Blueprint
experiment contains datasets for these histone marks in
umbilical cord blood CD14+ monocytes from three
healthy term neonates and peripheral blood CD14+
monocytes from three healthy adults. Information
obtained from each of these datasets was processed in the

























































Fig. 2 The number and location of H3K4me3 peaks throughout the monocyte genome change over the course of development. a Principle
component analysis showing clustering of experimental groups based on H3K4me3-binding sites and affinity for those sites. 1, 2, 3 = replicate number.
b H3K4me3 total peaks in the monocyte genome by age. Box represents mean, and bar represents SD. **p < 0.01, ***p < 0.001. c Location of H3K4me3
peaks in monocytes by age
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Fig. 3 Gene pathways enriched for H3K4me3 evolve throughout development and into adulthood. a Broad biological gene ontology pathways
associated with H3K4me3 monocyte peaks by age. The top non-synonymous biological gene ontology pathways associated with H3K4me3 peaks
in b under 30 week preterm monocytes, c over 30 week preterm monocytes, d term monocytes, and e adult monocytes
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same fashion as the H3K4me3 monocyte dataset described
above. The H3K4me3 dataset used for comparison is from
the neonatal and adult samples that we acquired and
processed, not from the Blueprint Consortium. Adult
monocytes had significantly more H3K4me3 than neonatal
monocytes, but less H3K4me1 (Fig. 4a). Both the neonatal
and adult monocytes had comparable amounts of
H3K9me3, H3K27me3, H3K27ac, and H3K36me3 peaks
(Fig. 4a). The broad genomic locations of the H3K9me3,
H3K27me3, H3K4me1, H3K27ac, and H3K36me3 marks
were not significantly different between the neonatal and
adult monocytes (Fig. 4b). A closer analysis of the location
of these marks in relation to each other demonstrated that
the repressive marks H3K9me3 and H3K27me3 shared
similar locations and the activating/enhancing marks
H3K4me3, H3K4me1 and H3K27ac shared similar
locations, while H3K36me3 had significantly different loca-
tions than the other marks (Fig. 4c). The histone modifica-
tions with the largest number of differentially bound peaks
between neonatal and adult monocytes were H3K4me3
and H3K4me1 (Fig. 4d). There were very few bivalent do-
mains, containing H3K4me3 and H3K27me3 or H3K9me3,
in the neonatal and adult monocytes (Additional file 3:
Figure S2). These results demonstrate that monocytes lose
the enhancer mark H3K4me1 and gain the activating mark
H3K4me3 as development progresses from neonate to
adult. Other histone modifications stay relatively constant
in both number and location.
Given the shift from high H3K4me1/low H3K4me3 in
neonatal monocytes to low H3K4me1/high H3K4me3 in
adult monocytes, we decided to more closely analyze the
location of these marks to determine if some of the
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Fig. 4 Monocytes display a decrease in the enhancer mark H3K4me1 with a parallel increase in the activating mark H3K4me3 as development
progresses from neonate to adult. a Total monocyte peak numbers of the histone modifications H3K4me3 (from our dataset), H3K9me3, H3K27me3,
H3K4me1, H3K27ac, and H3K36me3 (from the Blueprint Consortium) in term neonatal and adult CD14+ monocytes. *p < 0.05, **p < 0.01. b Genomic
location of histone modification peaks in term neonatal and adult monocytes. c Correlation heatmap comparing histone modification peak occupancy
sites. T = term monocytes, A = adult monocytes. d Number of differentially bound histone modification peaks between neonatal and adult monocytes
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neonatal H3K4me1 marks were being directly converted
to H3K4me3 in the adult monocytes or if the additional
H3K4me3 marks in the adults were being placed de
novo. Sites with increased H3K4me3-binding affinity in
adult monocytes were compared to sites with increased
H3K4me1-binding affinity in neonatal monocytes, and
significant overlap was noted (Fig. 5a). Approximately
12 % of the differentially bound H3K4me3 sites in adult
monocytes also contained differentially bound H3K4me1
in neonatal monocytes. The gene ontology pathways
associated with these overlapping marks are detailed in
Fig. 5b. A closer look at some of these genes revealed
that the increased H3K4me1 in the neonatal monocytes
shared an identical location with the increased
H3K4me3 in the adult monocytes, supporting the
hypothesis that a direct conversion between H3K4me1
and H3K4me3 is occurring at some genes during mono-
cyte development (Fig. 5c, d).
The presence and abundance of H3K4me3 in monocytes
influences immune function
Given the association of H3K4me3 with promoter and
5′ coding regions of actively transcribed genes, we evalu-
ated immunologically important monocyte genes with
H3K4me3 peaks surrounding their promoter regions
[27, 28]. The genes evaluated did not have other
differentially bound histone modification peaks within
2 kb of their TSSs. As preterm monocytes had very few
H3K4me3 peaks associated with promoter regions, we
focused solely on the function of term neonatal and
adult monocytes. Neonatal umbilical cord blood CD14+
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Fig. 5 A subset of H3K4me1 in neonatal monocytes appears to directly convert to H3K4me3 in adult monocytes. a Venn diagram showing that
approximately 12 % of H3K4me3 peaks differentially bound between neonatal and adult monocytes have differentially bound H3K4me1 peaks at
the same location. b Broad biological gene ontology pathways associated with shared adult H3K4me3 and term neonatal H3K4me1 peaks.
c MPEG1 and d LYZ have significantly increased H3K4me1 across the whole gene in neonatal monocytes without appreciable H3K4me3, which
seems to convert to H3K4me3 at identical locations in adult monocytes with a parallel decrease in H3K4me1. A = adult, T = term. H3K4me3 peaks
display the read coverage for H3K4me3 from one of the representative replicates from each group. Black bars display the H3K4me3 consensus
peaks after only peaks present in at least two replicates are combined and analyzed. MPEG1 macrophage expressed 1, LYZ lysozyme
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were cultured in vitro with LPS 100 ng/mL (TLR4 ligand,
simulates gram-negative bacterial infection) or polyI:C
25 μg/mL (TLR3 ligand, simulates viral infection), and mes-
senger RNA (mRNA) expression was measured before cul-
ture (unstimulated) or 2 h after stimulation and receptor
surface staining was measured before culture (unstimu-
lated) or 6 h after stimulation. Neither the neonatal nor
adult monocytes demonstrated significant up-regulation of
inflammatory gene expression upon polyI:C stimulation,
with no difference observed between the neonatal and adult
monocyte responses to TLR3 activation. Therefore, the
analysis of monocyte function included LPS stimulation
only. The evaluated genes were categorized by the amount
of bound H3K4me3 shared between adult and neonatal
monocytes and whether gene expression was present at
baseline or required LPS stimulation to be expressed. The
first category of genes had H3K4me3 peaks surrounding
promoters in the adult monocytes without any appreciable
peaks in the term neonatal monocytes. A subset of these
genes had increased gene expression and surface receptor
expression at baseline in the adult monocytes (Fig. 6a,
CCR2 as example), while another subset had increased gene
expression and surface receptor expression in the adult
monocytes only after LPS stimulation (Fig. 6b, CD300C as
example). The second category of genes had H3K4me3
peaks surrounding promoters in both the adult and term
neonatal monocytes but had differential binding with in-
creased binding amount and affinity in the adult mono-
cytes. These genes had increased gene expression in the
adult monocytes either at baseline or with LPS stimulation
depending on the function of the gene product (Fig. 6c,
ILF2 as example). The third category of genes had compar-
able H3K4me3 binding near promoters in both adult and
term neonatal monocytes with equivalent gene expression
and surface receptor expression both at baseline and upon
LPS stimulation (Fig. 6d, CXCR4 as example). Representa-
tive flow cytometry plots for these surface receptors are
shown in Additional file 4: Figure S3. The top 50 genes with
differentially bound H3K4me3 near their promoter sites
can be found in Additional file 1: Table S5. Consistent with
our conventional ChIP data, there was increased H3K4me3
binding at the promoter sites of IL1B and TNF with
increased mRNA gene expression and secreted protein
levels upon LPS stimulation (Additional file 5: Figure S4).
These results suggest that both the presence and abun-
dance of H3K4me3 at gene promoters are critical to pro-
moting active gene expression, rather than peak presence
alone. Figure 7 summarizes the main findings of this study.
Discussion
Around the time of birth, the immune system has to
transition from a sterile intrauterine environment to an
environment full of foreign antigens and microbes.
During this transition, the neonatal immune system
must avoid excessive pro-inflammatory responses so that
rapid colonization of the skin and gastrointestinal tract
with beneficial microbial organisms can occur [29, 30].
Disruption in normal neonatal microbial colonization
can have long-lasting deleterious effects and is thought
to contribute to the development of allergic diseases,
including asthma [31, 32]. The fetal and neonatal
immune system polarization toward immunomodulatory
type 2 cytokine responses rather than more adult-like
pro-inflammatory type 1 cytokine responses not only
aids in this transition but also leaves neonates highly
susceptible to infections [3, 7]. The factors controlling
the developmental progression of immature neonatal
immune responses to mature adult immune responses
are poorly understood, leaving a large deficit in our
ability to prevent, diagnose, and effectively treat neonatal
infections. The present study strongly suggests that
alterations in H3K4 methylation contribute to neonatal
innate immune deficits, especially noteworthy in pre-
term infants.
Our study is the first to evaluate the contribution of
histone modifications to the neonatal immune response
and demonstrates that monocytes have a developmentally
regulated loss of the poised enhancer mark H3K4me1 with
a concurrent gain of the activating mark H3K4me3. Other
histone modifications including H3K9me3, H3K27me3,
H3K27ac, and H3K36me3 stay relatively constant in both
number and location throughout development and are
unlikely to make a significant contribution to developmen-
tal specific changes in monocyte function. The poised
enhancer mark H3K4me1 and the active promoter mark
H3K4me3 do not co-localize, with genes either demonstrat-
ing high H3K4me1 and low H3K4me3 or the converse.
This may reflect the conversion of H3K4me1 to H3K4me3
through the intermediate H3K4me2 rather than a complete
loss or gain of histone methylation at these sites [33, 34]. In
agreement with this, we have identified a subset of genes in
which H3K4me1 appears to be directly converted to
H3K4me3 as development progresses with genes moving
from a “poised” to an active configuration. This subset of
genes only comprises a small amount (12 %) of the
H3K4me3 gained in monocytes as development progresses,
suggesting that the majority (88 %) of H3K4me3 is
deposited de novo.
H3K4me3 is typically located at promoter regions of
actively transcribed genes [22, 27], so it is interesting
that the majority of H3K4me3 in neonatal monocytes is
in noncoding regions of the genome, including introns
and intergenic regions. It is unclear what role H3K4me3
is playing in these locations, but it may be serving a
distal regulatory role that has not previously been
described. Most of the neonatal H3K4me3 intergenic
peaks are also present in the adult monocytes, so it
appears that the majority of the new H3K4me3 peaks
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gained throughout development are being deposited in
promoter and exon locations. Distinct differences also exist
in gene ontology pathways associated with H3K4me3 in
neonatal and adult monocytes. Neonatal monocytes have
numerous H3K4me3 peaks associated with developmen-
tally related pathways, but these peaks are not present in
adult monocytes. The neonatal monocytes also have signifi-
cantly less metabolic pathways associated with H3K4me3,
which is important because a metabolic shift from oxidative
phosphorylation to either glycolysis or lipid metabolism is
required to accommodate the induction of a large number
of genes upon immune cell activation [24, 25]. Recent
evidence suggests that neonatal immune cells lack the
ability to perform this metabolic shift [26]. We identified
multiple genes crucial to glycolysis and lipid metabolism
containing H3K4me3 peaks in adult monocytes with
decreased or absent H3K4me3 peaks in the neonatal mono-
cytes. In light of this, we believe that H3K4me3 may be an
important factor regulating the ability of monocytes to
undergo this critical metabolic shift, and a lack of this mark
in metabolic pathways in neonatal monocytes may contrib-
ute to their dampened inflammatory response. In addition,
adult monocytes have significantly more H3K4me3 peaks



























































































































































CXCR4 Monocyte Surface Staining
Fig. 6 Differential binding of H3K4me3 at gene promoter sites during monocyte development results in changes in gene and protein expression.
a The presence of H3K4me3 peaks around the promoter site of CCR2 in adult monocytes without an appreciable H3K4me3 peak in term neonatal
monocytes is associated with significantly more CCR2 mRNA expression and CCR2 surface staining by flow cytometry in unstimulated adult
monocytes. b The presence of H3K4me3 peaks around the promoter site of CD300C in adult monocytes without an appreciable H3K4me3 peak in
term neonatal monocytes is associated with significantly more CD300C mRNA expression and CD300C surface staining by flow cytometry in adult
monocytes only after LPS 100 ng/mL in vitro stimulation. c Increased H3K4me3 peaks around the promoter site of ILF2 in adult monocytes are
associated with significantly more ILF2 mRNA expression in unstimulated adult monocytes. d Comparable amounts of H3K4me3 peaks around the
promoter site of CXCR4 in adult and term neonatal monocytes are associated with comparable CXCR4 mRNA expression and CXCR4 surface staining
by flow cytometry in unstimulated monocytes. A = adult, T = term. H3K4me3 peaks display the read coverage for H3K4me3 from one of the
representative replicates from each group. Black bars display the H3K4me3 consensus peaks after only peaks present in at least two replicates are
combined and analyzed. For the mRNA studies, adult n = 9, term n = 9. For the flow cytometry studies, adult n = 4, term n = 5. *p < 0.05, **p < 0.01
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neonatal monocytes, and the expression of some genes vital
to the monocyte inflammatory response to pathogens are
decreased in neonates due to either a complete absence of
or decreased abundance of H3K4me3 at their promoters.
There are also numerous miR promoters with increased
H3K4me3 in adult monocytes, suggesting that the ability to
perform nuanced regulation of complex pathways in mono-
cytes is not fully developed until adulthood. The increased
H3K4me3 gained by monocytes during development
appears to “mature” the immune system, resulting in more
robust and appropriate inflammatory responses and optimal
clearance of pathogens. Taken together, these results suggest
that neonatal immune cells exist in an epigenetic state that
is distinctly different from adult immune cells and that this
epigenetic state is a major contributor to neonatal specific
immune responses.
The increase in H3K4me3 deposition that occurs
between extremely preterm and term infants appears to be
triggered solely by stage of development, as these mono-
cytes have yet to be exposed to the ex-utero environment.
This is consistent with what occurs during gamete forma-
tion and early embryo development, when conserved post-
translational histone modification additions and removals
allow reprogramming of the epigenetic landscape during a
critical developmental window [35]. However, the increase
in total H3K4me3 deposition between term neonatal to
adult monocyte likely results from a combination of
developmental-specific and environmental exposure-related
triggers. Stimulation of immune cells by pathogens or
cytokines can prompt the deposition or removal of
H3K4me3 at functionally important genes and is critical for
the establishment and maintenance of macrophage and
T cell phenotypes [36–39]. Other environmental exposures
can also alter histone modification patterns, including high-
fat diet, diabetes-associated hyperglycemia, and environ-
mental pollutants and toxins [40–43]. These exposure-
induced epigenetic alterations have also been shown to
occur at the level of bone marrow progenitor cells and can
be inherited by daughter cells, resulting in permanent and
heritable changes in histone modification patterns in
hematopoietic cells [41]. We postulate that the increased
H3K4me3 deposition seen in monocytes over the course of
postnatal development is prompted by exposure to the ex-
utero environment. We believe these environmental stimuli
prompt the appropriate methyltransferase(s) to deposit
H3K4me3 at and around gene promoter sites to remodel
the epigenetic landscape of the monocytes to a more ma-
ture and functional state.
There are some limitations to this study. We attempted
to control for expected variability in primary human mono-
cytes by using pooled neonatal samples and three replicates
in our ChIP-seq experiments, but there may have been
some sex-specific or genetic variability in H3K4me3
patterns that were masked by this approach. Additionally,
while we evaluated a broad number of histone modifica-
tions throughout monocyte development, there are likely
other factors that influence developmental-specific changes
in monocyte function, including other histone modifica-
tions (H3K79me2, H3K9ac, H4K20me1), DNA methyla-
tion, miR expression, and non-epigenetic factors that were
not included in our study.
Conclusions
Our study reveals an increase in monocyte H3K4me3
deposition at promoter sites of immunologically and meta-
bolically important genes as development progresses from
neonate to adult, which correlates with the ability to mount
a more robust inflammatory response. These results show
that neonatal monocytes have a unique histone modifica-
tion landscape that contributes to their attenuated response
to pathogens and contributes to the neonate’s vulnerability
to infection. Further studies are needed to determine the
factors regulating this developmental change in monocyte
H3K4me3 amount and location and whether these factors
can be targeted to improve neonatal outcomes before,
during, and after infection.
Methods
Participants
The research protocol was approved by the local Institu-
tional Review Board, and written informed consent was
obtained from adult participants and parents of all neonatal
participants. We prospectively enrolled term (gestational
age >37 weeks), late preterm (gestational age 30–36 weeks),
and extremely preterm (gestational age <30 weeks) infants
born at the University of Michigan Medical Center,
between May 2012 and August 2015. Exclusion criteria
included the presence of histologic chorioamnionitis. We
enrolled a total of 16 adults and 34 extremely preterm, 19










Time Time + microbial
      exposure
Fig. 7 Proposed scheme of the evolution of the monocyte histone
modification landscape over the course of development from preterm
neonate to adult
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Blood
Peripheral blood was collected from participating
healthy adults. Umbilical cord blood was collected from
participating infants immediately after the delivery of the
placenta. The blood was sent to the University of
Michigan blood bank and was stored at 4 °C. The umbil-
ical cord blood samples were retrieved from the blood
bank and were processed anywhere from day of life 1
through day of life 33, based on when parental informed
consent was obtained. The day of sample collection and
processing had no effect on the histone methylation of
any of the promoters studied. Cord blood samples used
to measure mRNA expression were collected no later
than day of life 5. Diluted blood (1:2 with sterile 0.9 %
saline) was used to harvest umbilical cord mononuclear
cells by Ficoll-Isopaque density gradient centrifugation.
Mononuclear cells were used for chromatin immunopre-
cipitation. Mononuclear cells were also subjected to
CD14+ magnetic cell isolation according to the manu-
facturer’s instructions (Miltenyi Biotec). On average, the
purity of the monocytes was greater than 90 % by CD14
flow cytometry. Isolated CD14+ cells were aliquoted into
cryovials in recovery cell culture freezing media (Life
Technologies) and were stored at −80 °C prior to use.
Chromatin immunoprecipitation (ChIP)
The total cells used for ChIP ranged from 8.0 × 105–4.1 ×
106 per sample. Cells were fixed for 10 min at 37 °C in
18.5 % paraformaldehyde. Glycine ×10 was added to
quench extra paraformaldehyde. Cells were washed on ice
with ice-cold PBS, were lysed in SDS lysis buffer (1 % SDS,
10 mM EDTA, 50 mM Tris-HCl), and underwent syringe
passage three times with a 27-gauge needle. The DNA was
sheared by ultrasonication for 3 × 10 s pulses at 50 % ampli-
tude (Branson Digital Sonifier 450). The lysates were
cleared by centrifugation and were diluted in ChIP dilution
buffer (0.01 % SDS, 1.1 % Triton X-100, 2 mM EDTA,
20 mM Tris-HCl, 150 mM NaCl). A sample of “input
DNA” was collected, totaling 5 % of the total chromatin,
and was stored at 4 °C. Protein-DNA complexes were
immunoprecipitated with 4 μg of the following antibodies
overnight at 4 °C with rotation: IgG (Millipore, PP64B),
H3K4me3 (Abcam, ab8580), and H3K27me3 (Active Motif,
39155). Antibody-protein-DNA complexes were captured
using salmon sperm DNA/protein A-agarose beads for 1 h
at 4 °C with rotation. The bead complexes were washed
with low-salt immune complex buffer (0.1 % SDS, 1 %
Triton X-100, 2 mM EDTA, 20 mM Tris-HCl, 150 mM
NaCl), high-salt immune complex buffer (0.1 % SDS, 1 %
Triton X-100, 2 mM EDTA, 20 mM Tris-HCl, 500 mM
NaCl), LiCl immune complex buffer (0.25 M LiCl, 1 %
NP40, 1 % deoxycholate, 1 mM EDTA, 10 mM Tris-HCl),
and TE buffer (10 mM Tris-HCl, 1 mM EDTA). The
protein-DNA complexes and the “input DNA” were then
eluted using a 1 % SDS, 0.1 M NaHCO3 buffer and were
disrupted by heating at 65 °C for 5–24 h. DNA was ex-
tracted using phenol/chloroform and ethanol precipitation.
Real-time PCR was conducted with the ABI Prism 7700 Se-
quence Detection System using the SYBR Green PCR re-
agent (Applied Biosystems) following the manufacturer’s
instructions. Dissociation curve analysis was performed
for all primers to ensure a single product with the ex-
pected melting curve characteristics. PCR was conducted
using promoter-specific ChIP primers (Additional file 1:
Table S6). Percent of input was calculated as follows:
%(ChIP/Total input) = 2^[(Ctinput − Log{20,2}) −CtChIP] ×
3 × 100 %.
Cell culture
Cryovials of CD14+ cells were thawed, and cells were
washed twice in sterile RPMI. Cells were then plated in
96-well polystyrene culture plates at 5 × 104 cells/well in
100 μl of RPMI medium containing 400 mM/L L-glutam-
ine, 10 % adult human serum, 1 % penicillin/streptamycin,
1 % sodium pyruvate, and 1 % nonessential amino acids.
The cells were stimulated with 100 ng/mL lipopolysac-
charide (Sigma, purified from E. coli 055:B5) or 25 μg/mL
polyI:C (Invivogen) and were incubated at 37 °C and 5 %
CO2. Cells were collected for mRNA processing 0 and 2 h
after stimulation, and supernatant was collected for
protein analysis 24 h after stimulation. Cells were
collected for flow cytometry 0 and 6 h after stimulation.
mRNA and protein measurement
At the time of cell collection, the cells were separated
from the supernatant by centrifugation at 5000 RPM for
5 min at 4 °C. Cellular mRNA was then extracted and
purified using an RNeasy Micro Kit (Qiagen) according
to the manufacturer’s instructions. Complementary
DNA was synthesized using murine leukemia virus
reverse transcriptase (Applied Biosystems) and incubated
at 37 °C for 90 min, followed by 95 °C for 5 min to stop
the reaction. Real-time quantitative PCR was multi-
plexed using Taqman primers with a FAM-conjugated
probe and 18 s with a VIC-conjugated probe (Applied
Biosystems) to measure transcription of CCR2, CD300C,
ILF2, CXCR4, IL1B, and TNF. Resulting mRNA levels
were normalized to the housekeeping gene 18s and
compared using the ΔCT method. All reactions were
run on an ABI Prism 7700 Sequence Detection System
using Universal PCR reagent (Applied Biosystems). The
protein levels of the cytokines IL-1β and TNF were
measured from cell culture supernatants by Bioplex
assay (Bio-Rad).
Flow cytometry
CD14+ monocytes were resuspended in PBS with 1 %
FCS and 0.002 M EDTA, and Fc receptors were blocked
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with purified human IgG. Surface markers were identified
using antibodies (clones) against the following antigens,
all from BioLegend: CD14 (M5E2), CCR2 (K036C2),
CD300C (TX45), and CXCR4 (12G5) each at a 1:100 dilu-
tion. Cells were labeled according to the manufacturer’s
instructions. Flow cytometry was performed on a
NovoCyte machine with 405, 488, and 640 nm lasers.
High throughput sequencing
Purified umbilical cord blood CD14+ monocytes (including
both CD16− and CD16+ subsets) of extremely preterm
infants (<30 weeks gestation), late preterm infants (30–
36 weeks gestation), term infants (37+ weeks gestation),
and healthy adults were used for ChIP-seq. Each age group
contained three biological replicates. To obtain approxi-
mately 1 × 106 cells per immunoprecipitation, each
neonatal sample replicate contained three pooled samples
(Additional file 1: Table S7). ChIP was performed as
described above, with modification of the following ultraso-
nication settings: 40 % amplitude, 0.7 s ‘on’, and 1.3 s ‘off ’
for 240 s on wet ice. The immunoprecipitation was
performed with 4 μg of the H3K4me3 antibody (Abcam,
ab8580). DNA from each ChIP experimental group was
treated with 30 μg RNase-A (Qiagen) and was incubated at
37° C with intermittent shaking for 1 h. The samples were
purified using a MinElute PCR purification kit (Qiagen)
following the manufacturer’s instructions. End repair of the
sonicated DNA was performed by incubating the samples
with a kinase mix (Additional file 1: Table S8) and incubat-
ing at 37 °C for 60 min, followed by incubation at room
temperature for 10 min. The samples were then incubated
with a blunting mix (Additional file 1: Table S9) at 16 °C
for 10 min, followed by 12 °C for 20 min, then incubation
on ice for 30 min. The samples were then purified using a
MinElute PCR purification kit (Qiagen) following the man-
ufacturer’s instructions. 3′ dA-tailing of the blunt DNA was
performed by adding a dA-tailing mix (Additional file 1:
Table S10) to each sample and incubating at 30 °C for
60 min. The samples were then purified using a MinElute
PCR purification kit (Qiagen) following the manufacturer’s
instructions. Oligonucleotide adapters and PCR primers are
shown in Additional file 1: Table S11. The universal for-
ward PCR primer was reconstituted to 25 μM in TE buffer,
and each of the reverse PCR primers was reconstituted to
10 μM in TE buffer and frozen at −80oC until use. Adapters
A and B were combined and reconstituted in 5X Crimson-
Taq Buffer (New England BioLabs) at a concentration of
5 μM each and were frozen at −80 °C until use. After
thawing, the A/B adapter mix was incubated on a PCR
machine with the following settings: 25 °C for 2 min, 95 °C
for 2 min, 72 °C for 1 min, 0.1 °C/s to 30 °C, 30 °C for
5 min, and 0.1 °C/s to 4 °C. The A/B adapter mix was then
diluted from 5 to 0.33 μM by adding 1X T4 DNA Ligase
Buffer (New England BioLabs) to the A/B adapter mix. The
A/B adapter mix was then placed on ice, and 20 μL of the
0.33 μM A/B adapter mix was added to each DNA sample.
A ligase mix was then added to each sample (Additional file
1: Table S12), and the samples were incubated at 22 °C for
4 h. The samples were then purified using a MinElute PCR
purification kit (Qiagen) following the manufacturer’s in-
structions. Adapter-adapter ligation products were removed
through RNACLEAN XP bead purification (Agencourt).
The clear supernatant containing the RNACLEAN XP
beads was used as PEG-wash Buffer. RNACLEAN XP
beads were resuspended by vortexing, and 150 μL was
added to each sample. The samples were incubated at 22 °
C on a thermomixer with maximum shaking for “1 min on
and 5 min off” for a total of 60 min. The samples were
placed on a magnetic stand (Millipore), and the supernatant
was removed. The beads were washed with the PEG-wash
buffer, and the samples were incubated on a thermomixer
at 22 °C for 2 min with maximum shaking. The samples
were placed back on the magnetic stand, and the super-
natant was removed. The samples were washed three times
with 80 % ethanol while remaining on the magnetic stand,
and the supernatant was discarded. The beads were then
allowed to dry by room temperature incubation. DNA was
eluted off the beads by adding TE buffer and alternating
2 min incubations at 42 °C and 5 s vortexes for a total of
8 min. The samples were placed back on the magnetic
stand, and the DNA containing supernatant was transferred
to a new tube. The samples were then purified using a
MinElute PCR purification kit (Qiagen) following the
manufacturer’s instructions. PCR reactions for multiplexed
sequencing were then set up by adding a forward primer
mix to each sample (Additional file 1: Table S13). The sam-
ples were incubated on ice for 5 min. Phusion Hot Start
Flex DNA Polymerase 1 μL (New England BioLabs) and a
designated reverse PCR primer 5 μL were added to each
sample. The samples were then incubated in a PCR
machine with the following settings: 80 °C for 2 min, 98 °C
for 1 min, 2 cycles [98 °C for 30 s, 60 °C for 30 s, 72 °C for
30 s], 13 cycles [98 °C for 30 s, 66 °C for 30 s, 72 °C for
30 s], 4 cycles [98 °C for 30 s, 66 °C for 30 s, 72 °C for 60 s],
and 72 °C for 7 min and then 4 °C. The samples were then
purified using a Qiaquick PCR purification kit (Qiagen)
following the manufacturer’s instructions. The samples
were then pooled in equimolar concentrations and single-
end ChIP-seq (50 nt) was performed on an Illumina HiSeq
machine, resulting in 10–20 million reads/sample. The
quality of samples was assessed using FastQC (http://
www.bioinformatics.babraham.ac.uk/projects/fastqc/) and
ChIPQC [44]. All samples passed quality control measures,
which are outlined in Additional file 1: Table S14.
ChIP-seq mapping and data analysis
This study makes use of data generated by the Blueprint
Consortium. A full list of the investigators who contributed
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to the generation of the data is available from http://
www.blueprint-epigenome.eu. Funding for the project was
provided by the European Union’s Seventh Framework
Programme (FP7/2007-2013) under grant agreement
no. 282510—BLUEPRINT. The Blueprint dataset utilized
was EGAD00001000913, which included ChIP-seq for
H3K9me3 (2 μg antibody, Diagenode), H3K27me3
(1 μg antibody, Diagenode), H3K4me1 (2 μg antibody,
Diagenode), H3K27ac (1 μg antibody, Diagenode), and
H3K36me3 (5 μg antibody, Diagenode) on CD14-positive,
CD16-negative classical monocytes from term neonatal
umbilical cord blood and adult peripheral blood. For each
of the histone modifications, three term neonatal samples
and three adult samples were analyzed from the raw reads.
Adapter sequences were trimmed from raw reads
using Scythe (https://github.com/vsbuffalo/scythe), and
the remaining reads were aligned to the Homo Sapiens
genome assembly (Build 37, hg19) using Bowtie2 version
2.0.0 with default parameters [45]. Results were normal-
ized to total read count. Peak calling was performed by
comparing the ChIP samples to input samples with
MACS2 [46]. Consensus peaksets were derived from the
biological replicates using DiffBind and peaks needed to
be present in two out of three replicates to be included in
the consensus peaksets [47]. These consensus peaksets
were then used for downstream analyses. Differentially
bound sites were identified, and differential analysis was
performed using the EdgeR package [48]. Sites were only
considered to be differentially bound if the false discovery
rate was <0.1. ChIPpeakAnno [49] was used to annotate
enriched peaks and identify Gene Ontology terms associ-
ated with adjacent genes.
Statistical analysis
Prism 6 was used for basic data analysis. The differences
between groups were evaluated with the student’s t test for
parametric quantitative data, the Mann-Whitney test for
nonparametric quantitative data, and ANOVA for multiple
comparisons of parametric data. Values of p < 0.05 were
considered to be significant.
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Additional file 1: Table S1. Total Number and Location of Monocyte
H3K4me3 Peaks by Age. Table S2. Immunologically Relevant Gene Ontology
Pathways Enriched for H3K4me3 in Monocytes. Table S3. microRNA
Promoters with Differentially Bound H3K4me3 Between Neonatal and Adult
Monocytes. Table S4. Genes Vital to Glycolysis and Lipid Metabolism with
Differentially Bound H3K4me3 Between Adult and Neonatal Monocytes.
Table S5. Gene Promoters with Differentially Bound H3K4me3 Between
Adult and Term Neonatal Monocytes. Table S6. ChIP Primers. Table S7.
ChIP-seq Patient Sample Composition. Table S8. ChIP-seq Kinase Mix.
Table S9. ChIP-seq Blunting Mix. Table S10. ChIP-seq dA-tailing Mix. Table
S11. ChIP-seq Oligonucleotide Adapters, Forward and Reverse PCR Primers.
Table S12. ChIP-seq Ligase Mix. Table S13. ChIP-seq Forward Primer Mix.
Table S14. H3K4me3 ChIP-seq Quality Control Data. (DOCX 41 kb)
Additional file 2: Figure S1. Gene ontology pathways associated with
H3K4me3 peaks present only in adult monocytes. (A) Broad biological gene
ontology pathways associated with H3K4me3 monocyte peaks present in
adult monocytes only. (B) Top 20 non-synonymous biological gene ontology
pathways associated with adult monocyte H3K4me3 peaks. (PDF 36 kb)
Additional file 3: Figure S2. There are very few bivalent domains in
neonatal and adult monocytes. (A) Venn diagram showing overlapping
adult monocyte consensus peaks for H3K4me3, H3K9me3, and
H3K27me3. (B) Venn diagram showing overlapping term neonatal
monocyte consensus peaks for H3K4me3, H3K9me3, and H3K27me3.
H3K4me3 consensus peaks are obtained after only peaks present in at
least two replicates are combined and analyzed. (PDF 680 kb)
Additional file 4: Figure S3. Adult monocytes demonstrate increased
levels of the surface receptors CCR2 and CD300C by flow cytometry. (A)
Representative density plot of CD14 + CCR2+ neonatal monocytes. (B)
Representative density plot of CD14 + CCR2+ adult monocytes. (C)
Representative density plot of CD14 + CD300C+ neonatal monocytes. (D)
Representative density plot of CD14 + CD300C+ adult monocytes. (E)
Representative density plot of CD14 + CXCR4+ neonatal monocytes. (F)
Representative density plot of CD14 + CXCR4+ adult monocytes. (PDF 425 kb)
Additional file 5: Figure S4. Differential binding of H3K4me3 at
pro-inflammatory cytokine promoters during development results in
differences in gene expression. (A) Increased binding of H3K4me3 at
the promoter site of IL1B in adult monocytes is associated with
increased IL1B mRNA and protein expression after LPS stimulation.
(B) Increased binding of H3K4me3 at the promoter site of TNF in adult
monocytes is associated with increased TNF mRNA and protein expression
after LPS stimulation. A = adult, T = term. H3K4me3 peaks display the read
coverage for H3K4me3 from one of the representative replicates from each
group. Black bars display the H3K4me3 consensus peaks after only peaks
present in at least two replicates are combined and analyzed. For the mRNA
studies, adult n= 5, term n= 5. For the protein studies, adult n= 4, term n= 4.
*p< 0.05, **p< 0.01. (PDF 215 kb)
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